CD19 and acute lymphoblastic leukemia: reported on a phase I/II trial using donor-derived CD19 CAR T-cells generated with the SB transposon and differentiated into cytokine-induced killer (CIK) cells for patients with B-ALL who relapsed after allogeneic HCT (29).